

**West of Scotland Cancer Network**  
**Haemato-oncology MCN Work Plan 2025/2026**

	Actions Required	Lead	Due Date
1.	Continue to engage with the Regional MDT Improvement Programme to optimise operational efficiency and effectiveness of the MDT		
1.1	Review the haemato-oncology specific data sets and definitions to ensure they remain fit for purpose and supplement the agreed ‘core’ data set for the application.	MCN Clinical Lead MCN&I Manager MCN Members	Mar 26
1.2	Work with MDT programme Board and eHealth colleagues to progress development of the MDT digital system ready for regional implementation, utilising the agreed haemato-oncology specific data sets.		TBC
2.	Collate national MDT or referral pathways for rare or hyper-orphan haematological malignancies and disorders		
2.1	Undertake scoping exercise to identify diseases to be covered.	MCN Clinical Lead MCN&I Manager MCN Members	Apr 25
2.2	Collate information on available pathways and national expertise.	MCN Clinical Lead MCN&I Manager MCN Members	Jun 25
2.3	Publish document collating above information on WoSCAN intranet site.	MCN Clinical Lead MCN&I Manager	Sep 25
3.	Undertake a non-interventional observational review of CLL patients treated with Acalabrutinib in the West of Scotland		
3.1	Request data from Chemocare.	MCN Clinical Lead MCN&I Manager MCN Members Senior Information Analyst (CEPAS)	Apr 25
3.2	Agree audit data fields and identify other data sources.	MCN Clinical Lead MCN&I Manager MCN Members	Sep 25
3.3	Conduct review and report findings.	MCN Clinical Lead MCN&I Manager MCN Members	Mar 26

	<b>Actions Required</b>	<b>Lead</b>	<b>Due Date</b>
<b>4.</b>	<b>Undertake an improvement project in partnership with pharma (Sanofi) to review the current SACT service for multiple myeloma and explore potential delivery of appropriate SACT medications within a home setting</b>		
4.1	Identify and approach appropriate clinical, managerial and service leads within NHSGGC to gain commitment to and sign off for the project.	MCN Clinical Lead MCN&I Manager	Apr 25
4.2	Conduct information gathering exercise with key stakeholders as outlined in Project Initiation Document.	MCN Clinical Lead MCN&I Manager MCN Members	Aug 25
4.3	Identify the potential benefits and drawbacks of implementing SACT delivery at home, both for specialist services and for patients.	MCN Clinical Lead MCN&I Manager MCN Members	Aug 25
4.4	Produce a report outlining the feasibility of and the resources and processes required to deliver any potential service redesign.	MCN Clinical Lead MCN&I Manager MCN Members	Oct 25
4.5	Consider extending the project to other WoS Boards, utilising the learning from the work undertaken in NHSGGC.	MCN Clinical Lead MCN&I Manager MCN Members	Dec 25
<b>5.</b>	<b>Undertake a post implementation audit of SACT approved medicines to assess service impact</b>		
5.1	Conduct audit and report findings.	MCN Clinical Lead MCN&I Manager WoS Pharmacy Team MCN Members	Oct 25
5.2	Revisit to assess if MCN is in agreement that this is a useful exercise to help plan service provision and development.	MCN Clinical Lead MCN&I Manager WoS Pharmacy Team Advisory Board	Mar 26
<b>6.</b>	<b>Rationalise and co-ordinate testing for haematological malignancies in the WoS</b>		
6.1	Identify other areas where regional diagnostic testing pathways would be appropriate and produce a phased plan for development.	MCN&I Manager Molecular Diagnostics Subgroup	Mar 26

	<b>Actions Required</b>	<b>Lead</b>	<b>Due Date</b>
6.2	Conclude the development of a CMG for Germline Predisposition.	Molecular Diagnostics Subgroup	Oct 25
6.3	Submit SG-TAG to expand Myeloid NGS panel scope.	Molecular Diagnostics Subgroup	TBC: SG-TAG process currently paused
<b>7.</b>	<b>Develop and maintain regional/national clinical guidelines to optimise patient care and lead on the development of national guidelines through collaboration with colleagues in SCAN/NCA</b>		
7.1	<b>CMGs</b> <ul style="list-style-type: none"> <li>• Myelodysplasia</li> <li>• Primary Cutaneous Lymphoma</li> <li>• Myeloma</li> <li>• Waldenstrom Macroglobulinaemia</li> <li>• Mature T cell Neoplasms</li> <li>• Mantle Cell Lymphoma</li> <li>• Prevention of anthracycline cardiotoxicity in haematological malignancies (NEW)</li> <li>• Scottish CMG for Classical Hodgkin Lymphoma</li> <li>• CML</li> <li>• Prophylaxis and Management of Tumour Lysis Syndrome in Adults</li> <li>• Management of newly presenting patients with a mediastinal mass causing airway compromise</li> </ul> <b>CGDs</b> <ul style="list-style-type: none"> <li>• Recommended Screening and Preventative Practices for Adult Long-Term Survivors after Allogeneic Haemopoietic Stem Cell Transplant and TBI Autografts</li> <li>• Regional guideline on the management of treatment induced premature menopause in patients with blood cancer (NEW)</li> </ul>	MCN Clinical Lead MCN&I Manager MCN Members	May 25 May 25 May 25 May 25 Aug 25 Sep 25 Sep 25 Oct 25 Oct 25 Oct 25 Dec 25  May 25  Jun 25
<b>8.</b>	<b>Use cancer data to drive improvement in quality of care and outcomes</b>		
8.1	Review QPI audit findings to identify variation in practice, identify requirements for further data analysis to aid understanding of variance and develop action/ improvement plans.	MCN Clinical Lead MCN&I Manager Information Team	Apr 25 (AL) Sep 25 (Lym)
8.2	Monitor and ensure progress with regional and local board action/improvement plans.	MCN&I Manager Board Clinical Effectiveness Leads	Mar 26

	Actions Required	Lead	Due Date
<b>9.</b>	<b>Deliver regional education event which facilitates review of clinical audit data and promotes shared learning of current best practice and innovation</b>		
9.1	Develop a focused programme and establish data requirements.	MCN Clinical Lead MCN&I Manager	Oct 25
9.2	Develop action plans arising from the event and monitor progress of agreed actions.	MCN Clinical Lead MCN&I Manager	Mar 26
<b>10.</b>	<b>Maintain regional service configuration map for haematological cancers</b>		
10.1	Update activity following publication of audit report.	MCN&I Manager	Dec 25